Merck, LabCorp in PGx Licensing Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merck said after the close the market yesterday that it has granted Laboratory Corporation of America a non-exclusive license to commercialize a genetic test to help predict patient response to peginterferon alpha-based therapy for hepatitis C virus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.